{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T14:25:57Z","timestamp":1792679157691,"version":"4.5.0"},"reference-count":20,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2023,1,18]],"date-time":"2023-01-18T00:00:00Z","timestamp":1674000000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2023,1,18]],"date-time":"2023-01-18T00:00:00Z","timestamp":1674000000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Advances in Wound Care"],"published-print":{"date-parts":[[2023,4]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To compare outcomes for Medicare patients with diabetic foot ulcer(s) (DFU) receiving cryopreserved placental membrane containing viable cells (vCPM) to other Cellular- and Tissue-Based Products (CTPs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Approach:<\/jats:title>\n                    <jats:p>Patients with DFU and CTP use were selected in Medicare claims (2013\u20132017) by using a strict definition of DFU with demonstrated diabetes etiology. We compared the effectiveness of vCPM with other CTPs on: (1) reduction of post-treatment ulcer occurrence, and (2) reduction in 1 year mortality. We controlled for selection bias and differential risk characteristics between comparison groups in a two-stage inverse probability treatment weighting model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Overall, 7,869 DFU episodes with CTP use met inclusion criteria: 786 received vCPM, 4,546 received another \u201ccellular\u201d CTP, and 2,537 received \u201cacellular\u201d CTP. For ulcer occurrence, we examined: 30-, 90-, 180-, and 365 days post-treatment. We found a significant reduction in ulcers at each period for vCPM compared with either alternative CTP\u2014results range from a 36.7% percentage point reduction in ulcer occurrence at 30 days compared with cellular CTP, and a 58.5% percentage point reduction at 365 days compared with acellular CTP. Further, the application of vCPM reduces mortality within 1 year by 2.3 percentage points (13\u201313.8% change) compared with other CTPs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Innovation:<\/jats:title>\n                    <jats:p>This study examines the differences in ulcer occurrence and mortality for Medicare DFU patients receiving vCPM and other CTPs. Our strict DFU definition excludes beneficiaries without foot ulcer with demonstrated diabetes etiology.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Among CTPs, vCPM users have reduced ulcer rates (recurrent or new) and reduced all-cause mortality compared with other \u201ccellular\u201d and \u201cacellular\u201d CTPs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/wound.2021.0123","type":"journal-article","created":{"date-parts":[[2022,3,9]],"date-time":"2022-03-09T08:38:17Z","timestamp":1646815097000},"page":"169-176","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":7,"title":["Cryopreserved Placental Membrane Allograft Reduces the Likelihood of Developing a New or Recurring Foot Ulcer and All-Cause Mortality in Diabetic Patients When Compared with Other Cellular- and Tissue-Based Products"],"prefix":"10.1177","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4121-8343","authenticated-orcid":false,"given":"Joan","family":"DaVanzo","sequence":"first","affiliation":[{"name":"Dobson DaVanzo and Associates, LLC, Vienna, Virginia, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Hartzman","sequence":"additional","affiliation":[{"name":"Dobson DaVanzo and Associates, LLC, Vienna, Virginia, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Surfield","sequence":"additional","affiliation":[{"name":"Dobson DaVanzo and Associates, LLC, Vienna, Virginia, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allen","family":"Dobson","sequence":"additional","affiliation":[{"name":"Dobson DaVanzo and Associates, LLC, Vienna, Virginia, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2023,1,18]]},"reference":[{"key":"e_1_3_5_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2017.07.007"},{"key":"e_1_3_5_3_2","doi-asserted-by":"publisher","DOI":"10.4239\/wjd.v6.i1.37"},{"key":"e_1_3_5_4_2","unstructured":"Local Coverage Determination (LCD): Wound Application of Cellular and\/or Tissue Based Products (CTPs) Lower Extremities (l36690). 2020. In Medicare Coverage Database. https:\/\/www.cms.gov\/medicare-coverage-database\/details\/lcd-details.aspx?LCDId=36690&ver=29&articleid=56696&keyword=grafix&keywordType=starts&areaId=all&docType=NCA%2cCAL%2cNCD%2cMEDCAC%2cTA%2cMCD%2c6% (last accessed June7 2019)."},{"key":"e_1_3_5_5_2","doi-asserted-by":"publisher","DOI":"10.5966\/sctm.2011-0018"},{"key":"e_1_3_5_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1615439"},{"key":"e_1_3_5_7_2","unstructured":"Skin Substitutes for Treating Chronic Wounds: Draft Technical Brief. 2019. In Technology Assessment Program. https:\/\/www.ahrq.gov\/sites\/default\/files\/wysiwyg\/research\/findings\/ta\/drafts-for-review\/skin-substitutes_draft.pdf (last accessed June24 2019)."},{"key":"e_1_3_5_8_2","doi-asserted-by":"publisher","DOI":"10.1089\/wound.2015.0636"},{"key":"e_1_3_5_9_2","doi-asserted-by":"publisher","DOI":"10.1089\/wound.2015.0637"},{"key":"e_1_3_5_10_2","doi-asserted-by":"publisher","unstructured":"Duan-Arnold Y Uveges TE Gyurdieva A Johnson A Danilkovitch A. Angiogenic potential of cryopreserved amniotic membrane is enhanced through retention of all tissue components in their native state. Adv Wound Care 2015. [Epub ahead of print]; DOI: 10.1089\/wound.2015.0638.","DOI":"10.1089\/wound.2015.0638"},{"key":"e_1_3_5_11_2","doi-asserted-by":"publisher","DOI":"10.1186\/1757-1146-3-27"},{"key":"e_1_3_5_12_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.27.suppl_2.B39"},{"key":"e_1_3_5_13_2","doi-asserted-by":"crossref","unstructured":"Skrepnek GH Mills JL Lavery LA Armstrong DG. Health care service and outcomes among an estimated 6.7 million ambulatory care diabetic foot cases in the U.S. Diabetes Care 2017;40:936\u2013942.","DOI":"10.2337\/dc16-2189"},{"key":"e_1_3_5_14_2","doi-asserted-by":"publisher","DOI":"10.1198\/000313004X5824"},{"key":"e_1_3_5_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/sim.2739"},{"key":"e_1_3_5_16_2","first-page":"192","article-title":"A classification of diabetes foot infections using ICD-9-CM codes: application to a large computerized medical database","volume":"10","author":"Finkle BG","year":"2019","unstructured":"Finkle BG, , Miller DR, , Turpin R. A classification of diabetes foot infections using ICD-9-CM codes: application to a large computerized medical database. BMC Health Serv Res, 2019; 10:192\u2013198.","journal-title":"BMC Health Serv Res"},{"key":"e_1_3_5_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(98)80044-1"},{"key":"e_1_3_5_18_2","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/2879249"},{"key":"e_1_3_5_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/wrr.12645"},{"key":"e_1_3_5_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/wrr.12503"},{"key":"e_1_3_5_21_2","doi-asserted-by":"publisher","DOI":"10.12968\/jowc.2021.30.Sup7.S5"}],"container-title":["Advances in Wound Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/wound.2021.0123","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/wound.2021.0123","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/wound.2021.0123","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T14:17:28Z","timestamp":1773238648000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/wound.2021.0123"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,18]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["10.1089\/wound.2021.0123"],"URL":"https:\/\/doi.org\/10.1089\/wound.2021.0123","relation":{},"ISSN":["2162-1918","2162-1934"],"issn-type":[{"value":"2162-1918","type":"print"},{"value":"2162-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,18]]}}}